Associate Director- External Innovation S&E Cardiovascular & Women’s Health at Eli Lilly and Company

Indianapolis, Indiana, United States

Eli Lilly and Company Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Healthcare, BiotechnologyIndustries

Requirements

  • PhD in Life Sciences related field, with track record in pre-clinical research, deep understanding of R&D processes and new modalities in the cardiometabolic and/or women’s health area
  • Minimum of 5 years of experience in the pharmaceutical industry
  • Strong scientific pedigree as evidenced by publications and presentations
  • Minimum of 2 years of experience in external research collaborations and S&E
  • Proven ability to work independently as well as in highly integrated cross functional teams (preferred)
  • Strong interpersonal and communication skills and the ability to represent Lilly in a highly professional manner (preferred)
  • Track record of attending scientific conferences in the cardiometabolic/WHS area and attending partnering conferences (preferred)
  • Demonstrated track record in managing complex collaborations (preferred)
  • 10-20% travel anticipated

Responsibilities

  • Identify and map new innovative opportunities with bold understanding of disease biology
  • Rigorously assess programs from biotech, small and large pharma companies for potential in-licensing/partnering opportunities that have been assigned for review by leadership or identified proactively
  • Manage all stages of partner interactions and evaluations, including initial contact, securing internal interest, meeting execution, coordinating internal debriefs, support DOCTA Search & Evaluation leadership as needed
  • Ensure prompt evaluation by functional experts (Biology, Chemistry, CMC, ADME, TOX, PK, legal etc.) for opportunity evaluation and pre-diligence and provide partners with essential feedback/guidance
  • Identify gaps and key issues and appropriate expertise to enable solutions
  • Collaborate with internal scientific teams to identify, design, and implement the scientific experiments necessary to validate external opportunities
  • Support consolidation of scientific feedback leading to internal recommendations and provision of partner responses
  • Maintain awareness of external competitive landscapes for key target areas and assets by actively monitoring all relevant external preclinical- and clinical-stage assets within therapeutic areas
  • Engage in partnering and scientific conferences as directed by DOCTA Search & Evaluation leadership to scout for new assets and technologies in line with R&D priorities
  • Provide regular updates at the EI deals review sessions

Skills

External Innovation
Search & Evaluation
Cardiovascular
Women’s Health
Disease Biology
Pipeline Development
Partner Management
In-Licensing
Business Evaluation
Scientific Assessment
Deal Negotiation
Biotech Evaluation
Pharma Partnerships

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI